Putting the ClinicalTrials.gov registry to work for patients,
science- and evidence-based medicine as the only reliable path
forward to improve outcomes for patients - present and future.
The patient has one life to experiment with; and dependents to
consider. Thus the decision to participate in a trial will be
based on the merits of doing so as a treatment decision - not to
advance the science or to help win marketing approval for a study
Therefore, the ideal clinical trial is a marriage of the best
science, rigorous study methods, and high-quality medicine.
For a clinical trial to enroll patients efficiently it must:
1) Compare well to
regular treatments -
or competing studies - as it relates to the
patient's clinical circumstance and treatment goals;
7 Reasons to Consider
Clinical Trials based on our Clinical Circumstances
2) The referring physician or patient must be aware of it --
it's location, eligibility criteria, and have good confidence in
the supporting science and evidence to date.
To address item 2, PAL provides queries of ClinicalTrials.gov
various ways in multiple venues:
- Through our website
- By posts made to our support forums
- By distribution notices made
to social media – Facebook and Twitter.
We have developed three main approaches
to finding trials listed here and illustrated below:
1. Following an
encouraging published report, by querying ClinicalTrials.gov for
open trials by the study agent
first diagnosis or relapsed, an appropriate study might be
located by narrowing the search - specific to
the type of lymphoma
and the patient’s treatment status (untreated, relapsed,
listing what we call PAL’s Picks – Trials of Interest
(grouped by type of lymphoma, in study drug order)
NOTE: PAL's Picks are studies that look promising to our group,
vetted by our scientific advisors, based on recent reports.
We list these in order to foster the conversation
about trials between patients and their treating physicians
- not to promote or match a patient to a particular trial.
PAL is committed to helping the community to appreciate how
study design influences the confidence that we can have in
the findings. We do our best to avoid hyping or
promoting specific approaches to treatment.
such as for
From this page
the community can:
name of agent to list articles on Google scholar.
Find trials to list files for this agent in the
the > symbol to see latest click count by bitley.
Reports to list published outcome reports on the
agent on Google Scholar
Find Trials By
TYPE of LYMPHOMA and TREATMENTS status
Here the QUERIES can help you to list only clinical
your type of lymphoma AND treatment status -
such as previously untreated follicular lymphoma.
From this page the visitor can:
Click the type of lymphoma for background on it, such as its
Click Untreated or Relapsed to list studies in the
ClinicalTrials.gov registry based on the diagnosis and treatment
Click the > symbol to see latest click count by bitley.
These are studies that look promising to our group and by our
scientific advisors based on recent reports. We list these in
order to foster the conversation about trials with the patient’s
oncologist or by consulting an expert for a second opinion.
We are very careful not to recommend participation in any
explaining how to use this page
OPTIONS FROM CLINICALTRIALS.GOV
After clicking some queries, you will see a
list of studies.
You can then click the
ON A MAP tab
to find the locations of the studies on a map.
You can also click a check box to show
only open studies
Click the protocol name to show the
details of the study, such as Contacts and Locations and Eligibility
Supporting efficient research and clinical
Patients and physicians must know what
trials are running in order to consider them. How else?
Our tools may also be useful to investigators
in order to judge interest in agents and to know what is being studied to guide in the
design of their trials.
Our Tools are Possible by Community Support
Our tools, and the related educational projects
would not be possible without the generous support of the patient
community. So we are taking time here to thanks all who have donated
and intend to do so soon.
PAL's continuing existence
truly depends on your help.
While the industry investment is
essential in order to bring new drugs to market, we have maintained
our financial independence so that you can be assured that a
financial interest is not guiding the content we provide.
Clinical Trial Tools At-a-Glance